Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539547 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3394266 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2621334 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3390883 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1521506 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854359 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854351 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1671746 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL342905 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL9961490 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060384-A | Biological method for preparing 1, 2-propanediol | 天津大学 | 2025-05-30 | — | — | CN | claimed |
| CN-120060228-A | Polypeptides for biosynthesis of 1, 2-propanediol and uses thereof | 天津大学 | 2025-05-30 | — | — | CN | claimed |
| CN-118961909-A | Burley tobacco baking uniformity evaluation method based on multi-index feature marker detection | 上海烟草集团有限责任公司 | 2024-11-15 | — | — | CN | claimed |
| CN-117903386-A | Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition | 厦门碳控科技投资有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | ISOTHRIVE LLC | 2024-02-08 | — | — | US | claimed |
| CN-116953112-A | Analysis method for simultaneously determining sugar, organic acid, amino acid and Maillard reaction product in tobacco flavor | 浙江中烟工业有限责任公司 | 2023-10-27 | — | — | CN | claimed |
| CN-115197780-A | Method for preparing heterocyclic compound from sugar-amino acid condensate and application of heterocyclic compound | 河南中烟工业有限责任公司 | 2022-10-18 | — | — | CN | claimed |
| CN-111638363-B | 3-deoxyfructose rapid quantitative fluorescence detection device and preparation method thereof | 吉林省格瑞斯特生物技术有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20210386683-A1 | COMPOSITIONS AND METHODS RELATING TO RESVERATROL | WILMORE LABS, LLC | 2021-12-16 | — | — | US | claimed |
| CN-111638363-A | 3-deoxyfructose rapid quantitative fluorescence detection device and preparation method thereof | 吉林省格瑞斯特生物技术有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-1148185-C | Inhibitor for generation of 3-deoxyglucurone | �ձ���ҩ��ʽ���� | 2004-05-05 | — | — | CN | claimed |
| WO-1999053930-A1 | SYNTHETIC GLYCOAMINES AND METHODS FOR THEIR USE, ALONE OR IN COMBINATION WITH OTHER THERAPIES, THAT AFFECT CELL ADHESION, INHIBIT CANCER CELL GROWTH AND METASTASIS, AND INDUCE APOPTOSIS | GLINSKII GUENNADI V (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0944639-A1 | SYNTHETIC GLYCOAMINES, METHODS FOR THEIR USE THAT AFFECT CELL | Glinskii, Guennadi, V. (US) | 1999-09-29 | — | — | EP | claimed |
| US-5864024-A | BRINGING CELLS INTO CONTACT WITH A COMPOUND COMPRISING A POLYPEPTIDE HAVING AN AMINO ACID LINKED TO A CARBOHYDRATE TO FORM A COMPOUND CHOSEN FROM THE GROUP CONSISTING OF SCHIFF BASES, N-GLYCOSIDES, ESTERS, AMADORI PRODUCTS | NIH - DEITR | 1999-01-26 | — | — | US | claimed |
| EP-0731704-A4 | SYNTHETIC GLYCOAMINES THAT PROMOTE OR INHIBIT CELL ADHESION | METASTAT INC (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1998023625-A9 | SYNTHETIC GLYCOAMINES, METHODS FOR THEIR USE THAT AFFECT CELL | — | 1998-09-17 | — | — | WO | claimed |
| WO-1998023625-A1 | SYNTHETIC GLYCOAMINES, METHODS FOR THEIR USE THAT AFFECT CELL | GLINSKII GUENNADI V (US) | 1998-06-04 | — | — | WO | claimed |
| US-5629412-A | POLYPEPTIDE AND CARBOHYDRATE | GLINSKII GUENNADI V (US) | 1997-05-13 | — | — | US | claimed |
| EP-0731704-A1 | SYNTHETIC GLYCOAMINES THAT PROMOTE OR INHIBIT CELL ADHESION | METASTAT, INC. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1996001639-A1 | SYNTHETIC GLYCOAMINES THAT PROMOTE OR INHIBIT CELL ADHESION | METASTAT, INC. (US) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | DDOST, STT3A, SI | PDE4A 2526/4885LMNA 689/4885L3MBTL1 1652/4885 |
| US-20210386683-A1 | COMPOSITIONS AND METHODS RELATING TO RESVERATROL | ATP6V1B2, PSEN1, APP | PDE4A 3528/4885LMNA 1214/4885L3MBTL1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.